AvalehtNOV • ETR
add
Novo Nordisk A/S
Viimane sulgemishind
80,19 €
Tänane vahemik
72,18 € - 81,10 €
Aasta vahemik
71,62 € - 138,48 €
Turuväärtus
264,44 mld USD
Keskmine maht
140,04 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
CPH
Uudised
NOVO-B
8,07%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(DKK) | dets 2024info | Y/Y muutus |
---|---|---|
Käive | 85,68 mld | 30,09% |
Põhitegevusega seonduv kulu | 31,04 mld | 13,28% |
Puhastulu | 28,23 mld | 28,53% |
Puhaskasumimarginaal | 32,95 | −1,20% |
Puhaskasum aktsia kohta | 6,34 | 29,12% |
EBITDA | 44,27 mld | 45,90% |
Tõhus maksumäär | 20,61% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(DKK) | dets 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 26,31 mld | −12,97% |
Kogu vara | 465,80 mld | 48,11% |
Kõik kohustused | 322,31 mld | 55,01% |
Kogu omakapital | 143,49 mld | — |
Emiteeritud aktsiate arv | 4,44 mld | — |
Hinna ja väärtuse suhe P/B | 2,48 | — |
Varade tasuvus | 24,66% | — |
Kapitali tasuvus | 50,24% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(DKK) | dets 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 28,23 mld | 28,53% |
Põhitegevuse rahakäive | 12,30 mld | 28,79% |
Investeeringute raha | −91,22 mld | −519,80% |
Finantseerimise raha | 36,84 mld | 464,13% |
Raha ja raha ekvivalentide muutus | −41,36 mld | −167,01% |
Tasuta rahavoog | −305,38 mln | 97,81% |
Teave
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph 𓃒. Wikipedia
Tegevjuht
Asutatud
21. dets 1923
Peakontor
Veebisait
Töötajate arv
76 826